Table 2. Univariate analysis or multivariate analysis based on the Cox proportional hazard regression model for RFS and OS in patients enrolled in training cohort or validation cohort or Two datasets merging.
| |
Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| Variables | HR (95% CI) | P-value | HR (95% CI) | P-value |
|
Training cohort—RFS | ||||
| AFU (⩽35 vs >35 u l−1) | 2.277 (1.864–2.780) | <0.001 | 1.738 (1.383–2.185) | <0.001 |
| Tumour size (⩽5 vs >5 cm) | 2.055 (1.693–2.494) | <0.001 | 1.663 (1.331–2.079) | <0.001 |
| GGT (⩽64 vs >64 u l−1) | 1.527 (1.258–1.854) | <0.001 | 1.159 (0.933–1.440) | 0.183 |
| AFP (⩽400 vs >400 ng ml−1) | 1.239 (1.028–1.492) | 0.024 | 0.905 (0.741–1.106) | 0.330 |
| Macrovascular invasion | 1.498 (1.146–1.958) | 0.003 | 1.248 (0.946–1.646) | 0.117 |
| ALP (⩽129 vs >129 u l−1) |
1.328 (1.084–1.627) |
0.006 |
0.998 (0.802–1.241) |
0.982 |
|
Training cohort—OS | ||||
| AFU (⩽35 vs >35 u l−1) | 2.461 (1.982–3.056) | <0.001 | 1.814 (1.421–2.315) | <0.001 |
| Tumour size (⩽5 vs >5 cm) | 2.116 (1.692–2.646) | <0.001 | 1.549 (1.208–1.985) | 0.001 |
| GGT (⩽64 vs >64 u l−1) | 1.788 (1.424–2.247) | <0.001 | 1.159 (0.893–1.504) | 0.269 |
| AFP (⩽400 vs >400 ng ml−1) | 1.543 (1.247–1.910) | <0.001 | 1.108 (0.883–1.391) | 0.376 |
| Macrovascular invasion | 2.444 (1.844–3.240) | <0.001 | 1.893 (1.411–2.539) | <0.001 |
| ALP (⩽129 vs >129 u l−1) | 1.514 (1.209–1.894) | <0.001 | 1.095 (0.859–1.395) | 0.463 |
| TB (⩽18.8 vs >18.8 mmol l−1) |
1.394 (1.122–1.734) |
0.003 |
1.354 (1.084–1.692) |
0.008 |
|
Validation cohort—RFS | ||||
| AFU (⩽35 vs >35 u l−1) | 1.392 (1.013–1.912) | 0.041 | 0.996 (0.691–1.437) | 0.984 |
| Tumour size (⩽5 vs >5 cm) | 1.417 (1.014–1.979) | 0.041 | 1.047 (0.718–1.527) | 0.811 |
| GGT (⩽64 vs >64 u l−1) | 1.543 (1.115–2.136) | 0.009 | 1.373 (0.956–1.974) | 0.086 |
| AFP (⩽400 vs >400 ng ml−1) | 1.6979 (1.235–2.333) | 0.001 | 1.533 (1.100–2.137) | 0.012 |
| Macrovascular invasion |
3.495 (2.246–5.440) |
<0.001 |
2.805 (1.756–4.480) |
<0.001 |
|
Validation cohort—OS | ||||
| AFU (⩽35 vs >35 u l−1) | 4.272 (2.446–7.461) | <0.001 | 2.333 (1.249–4.369) | 0.008 |
| Tumour size (⩽5 vs >5 cm) | 4.292 (2.246–8.202) | <0.001 | 2.081 (1.019–4.250) | 0.044 |
| GGT (⩽64 vs >64 u l−1) | 2.765 (1.622–4.712) | <0.001 | 1.500 (0.846–2.661) | 0.165 |
| AFP (⩽400 vs >400 ng ml−1) | 2.112 (1.329–3.357) | <0.001 | 1.642 (1.022–2.639) | 0.040 |
| Macrovascular invasion | 4.615 (2.747–7.754) | <0.001 | 2.352 (1.289–4.289) | 0.005 |
| ALP (⩽129 vs >129 u l−1) |
2.063 (1.271–3.348) |
0.003 |
1.095 (0.626–1.915) |
0.751 |
|
Two data sets merging—RFS | ||||
| AFU (⩽35 vs >35 u l−1) | 1.782 (1.509–2.104) | <0.001 | 1.369 (1.134–1.653) | 0.001 |
| Tumour size (⩽5 vs >5 cm) | 1.729 (1.464–2.042) | <0.001 | 1.387 (1.147–1.677) | 0.001 |
| GGT (⩽64 vs >64 u l−1) | 1.524 (1.291–1.801) | <0.001 | 1.238 (1.028–1.489) | 0.024 |
| AFP (⩽400 vs >400 ng ml−1) | 1.354 (1.153–1.590) | <0.001 | 1.102 (0.930–1.307) | 0.261 |
| Macrovascular invasion | 1.827 (1.453–2.297) | <0.001 | 1.516 (1.195–1.924) | 0.001 |
| ALP (⩽129 vs >129 u l−1) |
1.244 (1.041–1.487) |
0.016 |
0.963 (0.795–1.166) |
0.700 |
|
Two data sets merging—OS | ||||
| AFU (⩽35 vs >35 u l−1) | 2.500 (2.049–3.050) | <0.001 | 1.724 (1.376–2.160) | <0.001 |
| Tumour size (⩽5 vs >5 cm) | 2.229 (1.808–2.747) | <0.001 | 1.563 (1.239–1.972) | <0.001 |
| GGT (⩽64 vs >64 u l−1) | 1.929 (1.564–2.380) | <0.001 | 1.198 (0.945–1.519) | 0.136 |
| AFP (⩽400 vs >400 ng ml−1) | 1.664 (1.371–2.020) | <0.001 | 1.238 (1.010–1.518) | 0.040 |
| Macrovascular invasion | 2.863 (2.237–3.664) | <0.001 | 2.018 (1.557–2.615) | <0.001 |
| ALP (⩽129 vs >129 u l−1) | 1.636 (1.334–2.007) | <0.001 | 1.158 (0.930–1.442) | 0.189 |
| TB (⩽18.8 vs >18.8 mmol l−1) | 1.432 (1.173–1.748) | <0.001 | 1.380 (1.127–1.690) | 0.002 |
| Liver cirrhosis (yes vs no) | 1.326 (1.043–1.687) | 0.021 | 1.211 (0.949–1.547) | 0.124 |
Abbreviations: A=absence; AFP=alpha-fetoprotein; AFU=alpha-fucosidase; ALP=alkaline phosphatase; 95% CI=95% confidence interval; GGT=γ-glutamyl transpeptidase; HR=hazard ratio; OS=overall survival; P=presence; RFS=recurrence-free survival; TB=total bilirubin.
Macrovascular invasion, P vs A.
The clinicopathologic variables were adopted for their prognostic significance by univariate analyses.